Comecer has signed an agreement with Advaxis, a US-based biotechnology company, to produce an aseptic manufacturing system based on proprietary isolation technology.
Headquartered in Princeton, New Jersey (US), Advaxis is a late-stage biotechnology company creating cancer immunotherapies that enlist the body’s own immune system to fight cancer.
The agreement will see Comecer create a system to be used to develop immunotherapies based on Advaxis' immunotherapy research.
Alessia Zanelli, CEO of Comecer Group, commented: “When our equipment is used for such an important medical project, all of us at Comecer are proud. Being selected by Advaxis speaks to the quality of our solutions and confirms that our R&D investments are going in the right direction.”
Housed in Comecer's facilities, the GMP grade isolator technology will enable Advaxis to manufacturer its unique Listeria monocytogenes (Lm) targeted immunotherapy aimed at the production of a neoantigens. The system will be used for processing and expanding attenuated strains of Lm, which will be then bioengineered to secrete an antigen-adjuvant fusion protein.
The preparation will then be injected into the patient, to create a potent stimulation of their innate immune system. Due to the flexibility and adaptability of the manufacturing platform, the process can be adapted to target many different tumour types.
Headquartered in Italy, Comecer is a developer and manufacturer of high-tech systems in the field of aseptic processing and containment for the pharmaceutical and nuclear medicine industries. The company specialises in isolation technology solutions for regenerative medicine and tissue engineering.
Comecer also operates from locations in America, the Netherlands, India and Taiwan.
